[ Trevi Therapeutics raises $50.5M in Series C ]

Trevi Therapeutics has raised $50.5 million in Series C funding.

Founded in 2011, Trevi Therapeutics is a late-stage clinical development company focused on developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic and neuropathic conditions.

The Company plans to use the proceeds from the financing to advance the development of Nalbuphine® ER.

Funding  Series C
Founded  2011
Country  USA
City  Sandy Hook, Connecticut
Founder / CEO  Jennifer L. Good
Deal Size  $50.5M
Investors  New Enterprise Associates
 TPG Biotech
 Aperture Venture Partners
 Omega Funds
 Lundbeckfonden Ventures
Previous Investors  Solar capital
 TPG Biotech
 Square 1 Bank